NSCLC

You have access
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI and ANDREA BONETTI

Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550
You have access
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
ANA LAURA ORTEGA-GRANADOS, ÁNGEL ARTAL-CORTES, DAVID AGUIAR-BUJANDA, JUANA ORAMAS, JOSÉ LUIS FÍRVIDA, JAVIER DE CASTRO, JUANA CAMPILLO FUENTES, ROCÍO GORDO, RAQUEL GALÁN, JOSÉ TRIGO and on behalf of the ASPET Study Investigators

Anticancer Research March 2019, 39 (3) 1317-1328; DOI: https://doi.org/10.21873/anticanres.13244
You have access
Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review
ANISH B. PARIKH, LINDSAY HAMMONS and JORGE E. GOMEZ

Anticancer Research February 2019, 39 (2) 897-902; DOI: https://doi.org/10.21873/anticanres.13191
You have access
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
RALPH L. MILLETT, JACOB M. ELKON and IMAD A. TABBARA

Anticancer Research September 2018, 38 (9) 4969-4975; DOI: https://doi.org/10.21873/anticanres.12815
You have access
Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment
HIROMI FURUTA, TAKEHIRO UEMURA, TATSUYA YOSHIDA, MAKIKO KOBARA, TEPPEI YAMAGUCHI, NAOHIRO WATANABE, JUNICHI SHIMIZU, YOSHITSUGU HORIO, HIROAKI KURODA, YUKINORI SAKAO, YASUSHI YATABE and TOYOAKI HIDA

Anticancer Research September 2018, 38 (9) 5231-5237; DOI: https://doi.org/10.21873/anticanres.12847
You have access
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
MARIA BASSANELLI, STEFANO SIOLETIC, MAURIZIO MARTINI, SILVANA GIACINTI, ANTONELLA VITERBO, ANITA STADDON, FABRIZIO LIBERATI and ANNA CERIBELLI

Anticancer Research July 2018, 38 (7) 3789-3796; DOI: https://doi.org/10.21873/anticanres.12662
You have access
CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer
SEVERIN SCHMID, AGNES CSANADI, NIKOLA KOZHUHAROV, MARCEAU TCHUDJIN, CLAUDIA KAYSER, JUSTYNA RAWLUK, BERNWARD PASSLICK, MARTIN WERNER, ANTJE PRASSE and GIAN KAYSER

Anticancer Research July 2018, 38 (7) 3913-3918; DOI: https://doi.org/10.21873/anticanres.12676
You have access
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
HIROAKI TAKEOKA, KAZUHIKO YAMADA, YOSHIKO NAITO, NORIKAZU MATSUO, HIDENOBU ISHII, TAKAAKI TOKITO, KOICHI AZUMA, MASAO ICHIKI and TOMOAKI HOSHINO

Anticancer Research June 2018, 38 (6) 3779-3784; DOI: https://doi.org/10.21873/anticanres.12661
You have access
Correlation of Expression of Tenascin C and Blood Vessel Density in Non-small Cell Lung Cancers
ADAM RZECHONEK, JEDRZEJ GRZEGRZOLKA, PIOTR BLASIAK, MACIEJ ORNAT, ALEKSANDRA PIOTROWSKA, ALEKSANDRA NOWAK and PIOTR DZIEGIEL

Anticancer Research April 2018, 38 (4) 1987-1991;
You have access
SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma
NATALIA GLATZEL-PLUCINSKA, ALEKSANDRA PIOTROWSKA, JEDRZEJ GRZEGRZOLKA, MATEUSZ OLBROMSKI, ADAM RZECHONEK, PIOTR DZIEGIEL and MARZENNA PODHORSKA-OKOLOW

Anticancer Research February 2018, 38 (2) 723-736;

Main menu

User menu

Search

NSCLC

Pages